AAPL297.01-1.00 (-0.34%) ▼|ABBV230.01+13.52 (+6.25%) ▲|ABT87.83-0.58 (-0.66%) ▼|ACN124.83-3.15 (-2.46%) ▼|ADBE194.90-0.26 (-0.13%) ▼|AMAT640.18+23.07 (+3.74%) ▲|AMD551.63+14.26 (+2.65%) ▲|AMGN344.72+7.12 (+2.11%) ▲|AMT176.43+0.38 (+0.22%) ▲|AMZN232.79-11.60 (-4.75%) ▼|AVGO392.13-19.22 (-4.67%) ▼|AXP338.07+0.07 (+0.02%) ▲|BA220.83-1.89 (-0.85%) ▼|BAC57.37+1.17 (+2.08%) ▲|BKNG167.77-4.01 (-2.33%) ▼|BLK1,051.74+1.65 (+0.16%) ▲|BMY54.70+0.70 (+1.30%) ▲|BNY146.44+2.81 (+1.96%) ▲|BRK-B488.69-0.77 (-0.16%) ▼|C145.67+2.61 (+1.82%) ▲|CAT1,022.28+36.46 (+3.70%) ▲|CL88.67-0.81 (-0.91%) ▼|CMCSA22.32-0.11 (-0.49%) ▼|COF200.70-0.83 (-0.41%) ▼|COP109.70+1.96 (+1.82%) ▲|COST951.35-0.10 (-0.01%) ▼|CRM150.12-1.66 (-1.09%) ▼|CSCO121.53+1.99 (+1.66%) ▲|CVS101.30+2.98 (+3.03%) ▲|CVX175.06+1.43 (+0.82%) ▲|DE598.59+9.35 (+1.59%) ▲|DHR178.19+1.02 (+0.58%) ▲|DIS102.45-1.44 (-1.39%) ▼|DUK123.52-0.34 (-0.27%) ▼|EMR150.21-0.45 (-0.30%) ▼|FDX328.78+3.80 (+1.17%) ▲|GD343.36-6.65 (-1.90%) ▼|GE355.12-2.52 (-0.70%) ▼|GEV1,127.59+17.86 (+1.61%) ▲|GILD124.87+1.11 (+0.90%) ▲|GM80.43+1.14 (+1.44%) ▲|GOOG348.78-18.68 (-5.08%) ▼|GOOGL349.68-18.35 (-4.99%) ▼|GS1,106.37+9.81 (+0.89%) ▲|HD326.62-7.66 (-2.29%) ▼|HON228.11-0.90 (-0.39%) ▼|IBM252.22+3.12 (+1.25%) ▲|INTC140.94+6.95 (+5.19%) ▲|INTU257.77-9.23 (-3.46%) ▼|ISRG402.95-3.83 (-0.94%) ▼|JNJ231.29+2.90 (+1.27%) ▲|JPM331.48+6.26 (+1.92%) ▲|KO79.53+0.14 (+0.18%) ▲|LIN516.71+4.56 (+0.89%) ▲|LLY1,102.08+3.51 (+0.32%) ▲|LMT493.60-17.35 (-3.40%) ▼|LOW214.40-7.80 (-3.51%) ▼|LRCX409.54+20.50 (+5.27%) ▲|MA484.09-5.70 (-1.16%) ▼|MCD270.10-8.51 (-3.05%) ▼|MDLZ59.51-0.61 (-1.01%) ▼|MDT79.27-0.07 (-0.09%) ▼|META563.85-13.37 (-2.32%) ▼|MMM163.22+2.62 (+1.63%) ▲|MO69.51+0.39 (+0.56%) ▲|MRK115.48+1.61 (+1.41%) ▲|MS227.09+3.92 (+1.76%) ▲|MSFT367.34-12.06 (-3.18%) ▼|MU1,211.38+77.39 (+6.82%) ▲|NEE86.08-0.67 (-0.77%) ▼|NFLX72.88-4.50 (-5.82%) ▼|NKE43.19-2.01 (-4.45%) ▼|NOW93.01-2.03 (-2.14%) ▼|NVDA208.65-2.04 (-0.97%) ▼|ORCL175.07-9.22 (-5.00%) ▼|PEP140.71-1.31 (-0.92%) ▼|PFE25.08-0.13 (-0.52%) ▼|PG147.68-2.70 (-1.80%) ▼|PLTR119.50-8.97 (-6.98%) ▼|PM173.17-5.23 (-2.93%) ▼|QCOM221.90-4.21 (-1.86%) ▼|RTX181.83-3.77 (-2.03%) ▼|SBUX100.15-0.50 (-0.50%) ▼|SCHW92.03+0.33 (+0.36%) ▲|SO93.43+0.34 (+0.37%) ▲|SPG214.57+3.24 (+1.53%) ▲|T22.10+0.09 (+0.41%) ▲|TMO464.01-0.60 (-0.13%) ▼|TMUS180.06-1.61 (-0.89%) ▼|TSLA405.05+4.56 (+1.14%) ▲|TXN332.28+9.42 (+2.92%) ▲|UBER71.43-0.21 (-0.29%) ▼|UNH406.68+5.72 (+1.43%) ▲|UNP259.91+3.03 (+1.18%) ▲|UPS107.24+2.38 (+2.27%) ▲|USB58.68+0.54 (+0.93%) ▲|V326.60-0.64 (-0.20%) ▼|VZ45.36-0.01 (-0.02%) ▼|WFC83.84+1.64 (+2.00%) ▲|WMT117.18+0.00 (+0.00%) ▲|XOM138.47+0.66 (+0.48%) ▲|AAPL297.01-1.00 (-0.34%) ▼|ABBV230.01+13.52 (+6.25%) ▲|ABT87.83-0.58 (-0.66%) ▼|ACN124.83-3.15 (-2.46%) ▼|ADBE194.90-0.26 (-0.13%) ▼|AMAT640.18+23.07 (+3.74%) ▲|AMD551.63+14.26 (+2.65%) ▲|AMGN344.72+7.12 (+2.11%) ▲|AMT176.43+0.38 (+0.22%) ▲|AMZN232.79-11.60 (-4.75%) ▼|AVGO392.13-19.22 (-4.67%) ▼|AXP338.07+0.07 (+0.02%) ▲|BA220.83-1.89 (-0.85%) ▼|BAC57.37+1.17 (+2.08%) ▲|BKNG167.77-4.01 (-2.33%) ▼|BLK1,051.74+1.65 (+0.16%) ▲|BMY54.70+0.70 (+1.30%) ▲|BNY146.44+2.81 (+1.96%) ▲|BRK-B488.69-0.77 (-0.16%) ▼|C145.67+2.61 (+1.82%) ▲|CAT1,022.28+36.46 (+3.70%) ▲|CL88.67-0.81 (-0.91%) ▼|CMCSA22.32-0.11 (-0.49%) ▼|COF200.70-0.83 (-0.41%) ▼|COP109.70+1.96 (+1.82%) ▲|COST951.35-0.10 (-0.01%) ▼|CRM150.12-1.66 (-1.09%) ▼|CSCO121.53+1.99 (+1.66%) ▲|CVS101.30+2.98 (+3.03%) ▲|CVX175.06+1.43 (+0.82%) ▲|DE598.59+9.35 (+1.59%) ▲|DHR178.19+1.02 (+0.58%) ▲|DIS102.45-1.44 (-1.39%) ▼|DUK123.52-0.34 (-0.27%) ▼|EMR150.21-0.45 (-0.30%) ▼|FDX328.78+3.80 (+1.17%) ▲|GD343.36-6.65 (-1.90%) ▼|GE355.12-2.52 (-0.70%) ▼|GEV1,127.59+17.86 (+1.61%) ▲|GILD124.87+1.11 (+0.90%) ▲|GM80.43+1.14 (+1.44%) ▲|GOOG348.78-18.68 (-5.08%) ▼|GOOGL349.68-18.35 (-4.99%) ▼|GS1,106.37+9.81 (+0.89%) ▲|HD326.62-7.66 (-2.29%) ▼|HON228.11-0.90 (-0.39%) ▼|IBM252.22+3.12 (+1.25%) ▲|INTC140.94+6.95 (+5.19%) ▲|INTU257.77-9.23 (-3.46%) ▼|ISRG402.95-3.83 (-0.94%) ▼|JNJ231.29+2.90 (+1.27%) ▲|JPM331.48+6.26 (+1.92%) ▲|KO79.53+0.14 (+0.18%) ▲|LIN516.71+4.56 (+0.89%) ▲|LLY1,102.08+3.51 (+0.32%) ▲|LMT493.60-17.35 (-3.40%) ▼|LOW214.40-7.80 (-3.51%) ▼|LRCX409.54+20.50 (+5.27%) ▲|MA484.09-5.70 (-1.16%) ▼|MCD270.10-8.51 (-3.05%) ▼|MDLZ59.51-0.61 (-1.01%) ▼|MDT79.27-0.07 (-0.09%) ▼|META563.85-13.37 (-2.32%) ▼|MMM163.22+2.62 (+1.63%) ▲|MO69.51+0.39 (+0.56%) ▲|MRK115.48+1.61 (+1.41%) ▲|MS227.09+3.92 (+1.76%) ▲|MSFT367.34-12.06 (-3.18%) ▼|MU1,211.38+77.39 (+6.82%) ▲|NEE86.08-0.67 (-0.77%) ▼|NFLX72.88-4.50 (-5.82%) ▼|NKE43.19-2.01 (-4.45%) ▼|NOW93.01-2.03 (-2.14%) ▼|NVDA208.65-2.04 (-0.97%) ▼|ORCL175.07-9.22 (-5.00%) ▼|PEP140.71-1.31 (-0.92%) ▼|PFE25.08-0.13 (-0.52%) ▼|PG147.68-2.70 (-1.80%) ▼|PLTR119.50-8.97 (-6.98%) ▼|PM173.17-5.23 (-2.93%) ▼|QCOM221.90-4.21 (-1.86%) ▼|RTX181.83-3.77 (-2.03%) ▼|SBUX100.15-0.50 (-0.50%) ▼|SCHW92.03+0.33 (+0.36%) ▲|SO93.43+0.34 (+0.37%) ▲|SPG214.57+3.24 (+1.53%) ▲|T22.10+0.09 (+0.41%) ▲|TMO464.01-0.60 (-0.13%) ▼|TMUS180.06-1.61 (-0.89%) ▼|TSLA405.05+4.56 (+1.14%) ▲|TXN332.28+9.42 (+2.92%) ▲|UBER71.43-0.21 (-0.29%) ▼|UNH406.68+5.72 (+1.43%) ▲|UNP259.91+3.03 (+1.18%) ▲|UPS107.24+2.38 (+2.27%) ▲|USB58.68+0.54 (+0.93%) ▲|V326.60-0.64 (-0.20%) ▼|VZ45.36-0.01 (-0.02%) ▼|WFC83.84+1.64 (+2.00%) ▲|WMT117.18+0.00 (+0.00%) ▲|XOM138.47+0.66 (+0.48%) ▲|
21.3 C
New York
Tuesday, June 23, 2026

Tag: dose

newssourceFORcompanyinformationcontent1marketreleases

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically...

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more...

Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA

Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025

Bagsværd, Denmark, 20 June 2025 – Novo Nordisk announces subcutaneous amycretin data being presented at the American Diabetes Association (ADA) 85th Scientific Sessions in Chicago, US.1 Full results of two clinical trials evaluating the safety, tolerability and weight loss potential of subcutaneous and oral amycretin in people with overweight or obesity were published today in The Lancet medical journal.1,3 Amycretin is the first treatment that combines GLP-1 and amylin receptor agonism biology in a single molecule.

Studies show promising results for individuals with type 2 diabetes and young children with type 1 diabetes on MiniMed™ 780G system

Data supports the potential of future indication expansion for the MiniMed™ 780G system. LENNY trial results published in Lancet Diabetes & Endocrinology. GALWAY, Ireland and...

Stem Cell-Derived Islet Therapies Shown to Reduce the Need for Injectable Insulin

Breakthrough Studies Demonstrate Stem Cell-Based Technologies as a Potential Alternative Treatment for Type 1 Diabetes CHICAGO, June 20, 2025 /PRNewswire/ -- Findings from two studies...

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin...

SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced two upcoming late-breaking poster presentations at the American Diabetes Association 85th Scientific Sessions, being held from June 20-23 in Chicago, IL.

Novo Nordisk advances early-stage obesity medication, amycretin, to phase 3 clinical development based on early-phase clinical trial results in people with obesity or excess...

Both subcutaneous and oral formulations will advance straight to phase 3 development based on completed clinical studies and feedback received from regulatory authorities1,2PLAINSBORO, N.J.,...

Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007’s Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at...

Presentation to highlight WVE-007 (INHBE GalNAc-siRNA) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable reduction in Activin E resulting in fat loss with muscle preservation

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDose

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers